Scholarlink

<p>Anaphylaxis is a&#xa0;severe and potentially life-threatening condition characterized by a&#xa0;systemic hypersensitive reaction. It can be triggered by allergic or nonallergic pathways, with similar clinical symptoms in both cases. The release of mediators leads to peripheral vasodilatation, increased capillary permeability and enhanced mucosal secretion. Clinical signs include bronchospasm, laryngeal edema, tachycardia, arterial hypotension as well as gastrointestinal and cutaneous symptoms. Severe cases with primary cardiovascular arrest or airway obstruction can rapidly lead to death. The treatment strategies are guided by the clinical symptoms and the organ systems involved. In stage&#xa0;I basic measures include H1 or H2 histamine receptor antagonists and corticosteroids. In stages II–III, intramuscular adrenaline is used synergistically to stabilize the circulation and pulmonary function, while intravascular volume deficits are corrected with fluid replacement and vasopressors and airway obstruction is treated with β2 sympathomimetic drugs. In stage&#xa0;IV full cardiopulmonary resuscitation with mechanical chest compression and ventilation is additionally required. The timely intramuscular administration of adrenaline is crucial as it prevents severe courses and reduces the mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management der Anaphylaxie: Praxisempfehlungen für Rettungsdienst und Klinik

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Arend Rahrisch,
  • Manouk Feinendegen,
  • Andrea Christina Schiesser,
  • Patrick Schmithausen,
  • Jan Breckwoldt

摘要

Anaphylaxis is a severe and potentially life-threatening condition characterized by a systemic hypersensitive reaction. It can be triggered by allergic or nonallergic pathways, with similar clinical symptoms in both cases. The release of mediators leads to peripheral vasodilatation, increased capillary permeability and enhanced mucosal secretion. Clinical signs include bronchospasm, laryngeal edema, tachycardia, arterial hypotension as well as gastrointestinal and cutaneous symptoms. Severe cases with primary cardiovascular arrest or airway obstruction can rapidly lead to death. The treatment strategies are guided by the clinical symptoms and the organ systems involved. In stage I basic measures include H1 or H2 histamine receptor antagonists and corticosteroids. In stages II–III, intramuscular adrenaline is used synergistically to stabilize the circulation and pulmonary function, while intravascular volume deficits are corrected with fluid replacement and vasopressors and airway obstruction is treated with β2 sympathomimetic drugs. In stage IV full cardiopulmonary resuscitation with mechanical chest compression and ventilation is additionally required. The timely intramuscular administration of adrenaline is crucial as it prevents severe courses and reduces the mortality.